独立董事专门会议会议决议 浙江迦南科技股份有限公司 第六届董事会 2025 年第一次独立董事专门会议决议 浙江迦南科技股份有限公司（以下简称"公司"）第六届董事会 2025 年第 一次独立董事专门会议于 2025 年 4 月 16 日以现场方式召开。本次会议应出席独 立董事 3 人，实际出席会议 3 人，会议的召集、召开和表决程序符合《中华人民 共和国公司法》、《中华人民共和国证券法》、《上市公司独立董事管理办法》、 《浙江迦南科技股份有限公司章程》等相关规定。经会议审议，形成决议如下： 一、审议通过《关于 2024 年度利润分配预案的议案》 经核查，我们认为：公司 2024 年度利润分配预案综合考虑了公司情况，本 预案符合公司实际情况和长远发展战略，严格按照中国证监会《上市公司监管指 引第 3 号—上市公司现金分红》及《公司章程》等相关法律法规的规定，不存在 损害公司股东尤其是中小股东利益的情形。 综上所述，我们一致同意上述事项，并同意将该议案提交公司董事会和股东 大会审议。 表决结果：3 票同意，0 票反对，0 票弃权。 二、审议通过《关于 2024 年度内部控制自我评价报告的议案》 经核查，我们认为：报 ...

300412 证券代码：300412 证券简称：迦南科技 公告编号：2025-009 浙江迦南科技股份有限公司 第六届董事会第五次会议决议公告 一、董事会会议召开情况 1、会议通知时间与方式 浙江迦南科技股份有限公司（以下简称"公司"）第六届董事会第五次会议 通知于 2025 年 4 月 7 日以通讯方式送达全体董事 2、会议召开的时间、地点和方式 （1）会议时间：2025 年 4 月 17 日上午 9:00 （2）召开地点：公司会议室 （3）召开方式：以现场方式召开 （4）董事出席会议情况：应出席董事 9 人，实际出席董事 9 人 （5）主持人：董事长方正先生 （6）列席人员：监事及部分高级管理人员 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 本次会议符合《公司法》和《公司章程》等有关规定，所作的决议合法有效。 二、董事会会议审议情况 1.审议通过《关于 2024 年度总裁工作报告的议案》 表决结果：9 票同意，0 票反对，0 票弃权。 2.审议通过《关于 2024 年度董事会工作报告的议案》 具体内容详见同日披露在巨潮资讯网的《2024 年年度报告全文 ...

300412 证券代码：300412 证券简称：迦南科技 公告编号：2025-011 浙江迦南科技股份有限公司 关于 2024 年度利润分配预案的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 特别提示： 1、2024年度利润分配预案为：以2024年12月31日的公司总股本497,756,637 股为基数，向全体股东每 10 股派发现金红利 0.6 元（含税），以此计算合计拟 派发现金红利 29,865,398.22 元（含税），本年度不进行送股及资本公积金转增 股本。本次利润分配后公司剩余未分配利润滚存至下一年度。 2、公司现金分红预案不触及《深圳证券交易所创业板股票上市规则》第 9.4 条相关规定的可能被实施其他风险警示情形。 浙江迦南科技股份有限公司（以下简称"公司"）根据中国证券监督管理委 员会《上市公司监管指引第 3 号——上市公司现金分红》及《公司章程》等规定， 为充分考虑对投资者的回报，结合公司 2024 年度实际生产经营情况及未来发展 前景，于 2025 年 4 月 17 日召开第六届董事会第五次会议及第六届监事会第五次 会议审议通过了《 ...

300412 证券代码：300412 证券简称：迦南科技 公告编号：2025-019 浙江迦南科技股份有限公司 为优化公司管理架构，提高运营效率，降低管理成本，公司全资子公司迦楠 （天津）科技有限公司（以下简称"天津迦楠"）拟吸收合并北京迦南莱米特科 技有限公司（以下简称"迦南莱米特"）。本次吸收合并完成后，迦南莱米特的 独立法人资格将被注销，其全部资产、负债、权益、业务等将由天津迦楠承继。 本次吸收合并不构成关联交易，亦不构成《上市公司重大资产重组管理办法》 规定的重大资产重组。此事项在公司董事会批准权限内，无须提交股东大会审议。 二、交易对方、交易标的基本情况 （一）交易对方（被合并方）基本情况 统一社会信用代码：91110114554877066Y 法定代表人：王洪海 1 名 称：北京迦南莱米特科技有限公司 类 型：有限责任公司（法人独资） 住 所：北京市昌平区北七家镇宏福大厦1003室 关于调整子公司股权结构的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 浙江迦南科技股份有限公司（以下简称"公司"或"迦南科技"）于 2025 年 4 月 17 ...

浙江迦南科技股份有限公司 年度募集资金存放与使用情况鉴证报告 中国杭州市钱江新城新业路 8 号 UDC 时代大厦 A 座 5-8 层、12 层、23 层 www.zhcpa.cn Floors5-8,12and23,Block A,UDC Times Building,No.8 Xinye Road，Qianjiang New City,Hangzhou Tel.0571-88879999 Fax.0571-88879000 | | | | | 页 次 | | --- | --- | | 一、年度募集资金存放与使用情况鉴证报告 | 1-2 | | 二、浙江迦南股份有限公司关于 2024 年度募集资金 | | | 存放与使用情况的专项报告 | 3-8 | 中国杭州市钱江新城新业路 8 号 UDC 时代大厦 A 座 5-8 层、12 层、23 层 www.zhcpa.cn Floors5-8,12and23,Block A,UDC Times Building,No.8 Xinye Road，Qianjiang New City,Hangzhou Tel.0571-88879999 Fax.0571-888790 ...

关于浙江迦南科技股份有限公司 非经营性资金占用及其他关联资金往来情况的专项审核说明 中国杭州市钱江新城新业路 8 号 UDC 时代大厦 A 座 5-8 层、12 层、23 层 www.zhcpa.cn Floors5-8,12and23,Block A,UDC Times Building,No.8 Xinye Road，Qianjiang New City,Hangzhou Tel.0571-88879999 Fax.0571-88879000 目 录 | | 页 次 | | | --- | --- | --- | | 一、非经营性资金占用及其他关联资金往来情况的专项 | | | | 审核说明 | | 1-2 | | 二、非经营性资金占用及其他关联资金往来情况汇总表 | | 3-4 | 中国杭州市钱江新城新业路 8 号 UDC 时代大厦 A 座 5-8 层、12 层、23 层 www.zhcpa.cn Floors5-8,12and23,Block A,UDC Times Building,No.8 Xinye Road，Qianjiang New City,Hangzhou Tel.0571-888799 ...

浙江迦南科技股份有限公司 内部控制审计报告 中国杭州市钱江新城新业路 8 号 UDC 时代大厦 A 座 5-8 层、12 层、23 层 www.zhcpa.cn Floors5-8,12and23,Block A,UDC Times Building,No.8 Xinye Road，Qianjiang New City,Hangzhou Tel.0571-88879999 Fax.0571-88879000 内部控制审计报告 中汇会审[2025]4451号 浙江迦南科技股份有限公司全体股东： 按照《企业内部控制审计指引》及中国注册会计师执业准则的相关要求，我 们审计了浙江迦南科技股份有限公司(以下简称迦南科技公司)2024年12月31日的 财务报告内部控制的有效性。 一、企业对内部控制的责任 中国杭州市钱江新城新业路 8 号 UDC 时代大厦 A 座 5-8 层、12 层、23 层 www.zhcpa.cn Floors5-8,12and23,Block A,UDC Times Building,No.8 Xinye Road，Qianjiang New City,Hangzhou Tel.0571-8887 ...

中国杭州市钱江新城新业路 8 号 UDC 时代大厦 A 座 5-8 层、12 层、23 层 Floors5-8, 12and23,Block A,UDC Times Building,No.8 Xinye Road，Qianjiang New City,Hangzhou Tel.0571-88879999 Fax.0571-88879000 www. zhcpa. cn | 28 | | --- | | | 页 次 | | --- | --- | | -、审计报告 | 1-5 | | 二、财务报表 | 6-17 | | (一) 合并资产负债表 | 6-7 | | (二) 合并利润表 | 8 | | (三) 合并现金流量表 | 9 | | （四） 合并所有者权益变动表 | 10-11 | | (五) 母公司资产负债表 | 12-13 | | (六) 母公司利润表 | 14 | | (七) 母公司现金流量表 | 15 | | (八) 母公司所有者权益变动表 | 16-17 | 中国杭州市钱江新城新业路 8 号 UDC 时代大厦 A 座 5-8 层、12 层、23 层 Floors5-8, 12and23,Bloc ...

一、募集资金基本情况 （一）募集资金到位情况 经中国证券监督管理委员会《关于同意浙江迦南科技股份有限公司向特定对 象发行股票注册的批复》（证监许可[2021]1175 号），同意公司向特定对象发行 股票的注册申请。公司向 12 名特定对象发行人民币普通股（A 股）股票 35,573,122 股，发行价格 7.59 元/股，募集资金总额为人民币 269,999,995.98 元，扣除各项 发行费用人民币 8,137,735.84 元（不含增值税），募集资金净额为人民币 261,862,260.14 元。该募集资金截至 2021 年 12 月 3 日已全部到账。上述资金到 位情况已经中汇会计师事务所（特殊普通合伙）验证，并出具了《浙江迦南科技 股份有限公司验资报告》（中汇会验[2021]7839 号）。 国投证券股份有限公司 关于浙江迦南科技股份有限公司 2024 年度募集资金存放与使用情况的专项核查报告 国投证券股份有限公司（以下简称"国投证券"或"保荐机构"）作为浙江 迦南科技股份有限公司（以下简称"迦南科技"、"上市公司"或"公司"）2020 年度向特定对象发行股票的保荐机构，根据《证券发行上市保荐业务管理 ...

Financial Performance - The company's operating revenue for 2024 reached ¥1,383,110,540.27, representing a 32.09% increase compared to ¥1,047,093,891.26 in 2023[18]. - Net profit attributable to shareholders was ¥36,266,978.88 in 2024, a significant turnaround from a loss of ¥23,433,467.29 in 2023, marking a 254.77% improvement[18]. - The net cash flow from operating activities increased by 289.70% to ¥119,463,611.61 in 2024, compared to a negative cash flow of ¥62,974,373.07 in 2023[18]. - Basic earnings per share improved to ¥0.07 in 2024 from a loss of ¥0.05 in 2023, reflecting a 240.00% increase[18]. - The company's total revenue for 2024 reached ¥1,383,110,540.27, representing a 32.09% increase compared to ¥1,047,093,891.26 in 2023[71]. - The pharmaceutical equipment sector generated ¥1,165,731,743.04, accounting for 84.28% of total revenue, with a year-on-year growth of 17.44%[71]. - The oral solid dosage equipment sales amounted to ¥806,565,253.23, making up 58.32% of total revenue, reflecting a 17.63% increase from the previous year[71]. - The gross profit margin for the pharmaceutical equipment industry was 28.37%, showing a slight decrease of 0.06% year-on-year[73]. - The company's revenue from the pharmaceutical equipment industry reached ¥1,165,731,743.04, with a year-on-year increase of 17.44%[73]. - Domestic sales accounted for 93.38% of total revenue, amounting to ¥1,291,535,409.58, reflecting a 32.95% increase year-on-year[73]. Dividend and Profit Distribution - The company plans to distribute a cash dividend of 0.6 yuan per 10 shares (including tax) based on a total of 497,756,637 shares[5]. - The company has a cash dividend amount of 29,865,398.22 CNY, which represents 100% of the total profit distribution[162]. - The cash dividend per 10 shares is 0.6 CNY, reflecting the company's commitment to returning value to shareholders[161]. - The company has a clear and transparent profit distribution policy, ensuring the protection of minority shareholders' rights[160]. - The company has not issued any bonus shares or stock increases during the reporting period[162]. Risk Management and Compliance - The company emphasizes the importance of risk awareness regarding forward-looking statements and future plans[5]. - The company has outlined potential risks and corresponding countermeasures in its management discussion and analysis section[5]. - The company acknowledges risks from policy changes in the pharmaceutical industry that could impact demand for its products[120]. - The company faces intensified competition in the domestic pharmaceutical equipment market, particularly from established foreign manufacturers[120]. - The company is committed to optimizing its management system and establishing a scientific compensation management system to attract and retain talent[122]. - The company is focused on ensuring project progress and quality to mitigate risks associated with fundraising project implementation[123]. - The company has committed to enhancing compliance awareness regarding the use of raised funds following recent warnings issued to certain executives[185]. Corporate Governance - The company has a governance structure that includes a board of 9 members, with 3 independent directors, complying with legal and regulatory requirements[130]. - The company held multiple shareholder meetings in 2024, with participation rates ranging from 32.83% to 35.23%[135]. - The company completed a board election on July 23, 2024, resulting in the appointment of several new directors and executives[139]. - The total remuneration for directors, supervisors, and senior management during the reporting period amounted to CNY 3.49 million[146]. - The decision-making process for remuneration involves the shareholders' meeting for directors and supervisors, while the board decides for senior management[145]. - The independent directors include 樊德珠, 许小明, and 郑高利, each receiving CNY 72,000[146]. - The company has maintained a stable management team with no significant changes in shareholding among directors and executives during the reporting period[137]. - The company emphasizes close communication with the original management teams of the acquired subsidiaries to ensure stability and synergy in operations[124]. Research and Development - The company has established a comprehensive service capability across the entire pharmaceutical value chain, including information consulting, pharmaceutical research, equipment support, and clinical trials[62]. - The company aims to enhance its service capabilities and expand its market share by integrating upstream and downstream resources and improving equipment quality[41]. - The company is committed to building a digital capability matrix covering drug discovery, process development, and quality control to support the pharmaceutical 4.0 era[113]. - The company will strengthen its R&D capabilities by collaborating with universities to meet or exceed new GMP standards and enhance product intelligence[114]. - The company has developed a fully automated buffer liquid dispensing system, enhancing product efficiency and market competitiveness[85]. - The company has completed the development of a continuous production equipment for solid oral dosage forms, integrating filtration, washing, and drying processes into one machine, enhancing product efficiency and market competitiveness[84]. - The company is focusing on the optimization of high-efficiency stirring and extrusion screw structures for large-scale hot melt extrusion production lines, aiming for intelligent control technology[84]. - The company's R&D investment amounted to ¥80,755,686.14 in 2024, representing 5.84% of operating revenue, a decrease from 8.00% in 2023[87]. Market Position and Strategy - The company operates in the pharmaceutical equipment industry, which is characterized by strong demand and minimal seasonality[28]. - The company is a leader in the manufacturing of intelligent factory equipment for oral solid dosage forms, providing comprehensive solutions to pharmaceutical enterprises[28]. - The company has established a solid customer base, serving over 50 countries and regions, including well-known pharmaceutical and healthcare enterprises[28]. - The company aims to become a leading supplier of intelligent factory solutions in the pharmaceutical equipment market by 2025, focusing on solid preparation and health industry strategies[112]. - The company plans to enhance its product offerings in biopharmaceuticals, including improvements in medical water purification systems and related equipment[112]. - The company will increase investment in new product development and capacity expansion, targeting high-end manufacturing and automation[113]. - The company is focused on developing new products and technologies to meet the demands of both domestic and international high-end clients[63]. Internal Control and Audit - The internal control system has been updated and improved, effectively preventing operational risks and enhancing management oversight[165]. - No significant internal control deficiencies were reported during the period, with zero major defects identified in both financial and non-financial reporting[170]. - The internal control audit report confirmed that the company maintained effective financial reporting controls as of December 31, 2024[170]. - The company has appointed Zhonghui Certified Public Accountants as the internal control auditing firm, with a fee of 200,000 RMB[182]. Investment and Financing - The company raised a total of CNY 27,000.00 million through a non-public offering, with a net amount of CNY 26,186.23 million after deducting fees[102]. - As of December 31, 2024, the company had used CNY 16,297.69 million of the raised funds, with a remaining balance of CNY 10,799.32 million[103]. - The company has ongoing construction projects, including the "High-end Intelligent Medical Equipment Production Base" and "Pharmaceutical Liquid Preparation System Production Center" funded by self-raised capital and non-public offering funds[98]. - The total amount of guarantees approved during the reporting period is 35,000 million[199]. - The actual amount of guarantees that occurred during the reporting period is 6,960 million[199]. - The total amount of guarantees at the end of the reporting period is 9,985 million[199]. - The company has provided guarantees for loans to its controlling subsidiaries, with financial risks being within controllable limits[200]. Employee and Talent Management - The total number of employees at the end of the reporting period is 1,640, with 660 in the parent company and 980 in major subsidiaries[157]. - The company maintains a performance-based salary policy, linking compensation to individual and team performance[158]. - The company plans to enhance training programs in 2025, focusing on employee development and aligning with its core values[159]. - The company has a total of 48 employees with a postgraduate degree, highlighting its investment in skilled talent[157]. Environmental and Social Responsibility - The company has not faced any major environmental penalties during the reporting period and complies with relevant environmental laws[172]. - The company has not yet initiated any poverty alleviation or rural revitalization efforts during the reporting period[175]. - The company actively respects and protects the rights of stakeholders, promoting a balanced development approach[132].